Status:
COMPLETED
Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam
Lead Sponsor:
Yonsei University
Conditions:
Stomach Neoplasm
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Patients undergoing endoscopic submucosal dissection with monitored anesthesia care (MAC) using remimazolam may develop respiratory distress during the procedure. In these cases, substandard doses of ...
Detailed Description
Study patients will be patients scheduled for ESD in our gastroenterology department, and blood pressure and pulse measured in the pre-procedure room will be considered baseline vital signs. At the st...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists (ASA) class I-III
- 19 years of age or older
- Scheduled for gastric ESD by MAC with remimazolam
- Hemodynamically stable patients.
Exclusion
- Patients who have airway-related anatomic abnormalities
- Being requested by the endoscopist to be fully awake from anesthesia for any reason other than respiroatyr distress during the procedure
- Being administered any sedative other than remimazolam during the procedure (e.g., propofol, dexmedetomidine, etc.)
Key Trial Info
Start Date :
August 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06563063
Start Date
August 23 2023
End Date
December 1 2023
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea